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Abstract Primary extracranial meningiomas are rare
neoplasms, frequently misdiagnosed, resulting in inappro-
priate clinical management. To date, a large clinicopatho-
logic study has not been reported. One hundred and
forty-six cases diagnosed between 1970 and 1999 were
retrieved from the ﬁles of the Armed Forces Institute of
Pathology. Histologic features were reviewed, immuno-
histochemistry analysis was performed (n = 85), and
patient follow-up was obtained (n = 110). The patients
included74 (50.7%) females and 72 (49.3%) males. Tumors
of the skin were much more common in males than females
(1.7:1). There was an overall mean age at presentation of
42.4 years, with a range of 0.3–88 years. The overall mean
age at presentation was signiﬁcantly younger for skin
primaries (36.2 years) than for ear (50.1 years) and nasal
cavity (47.1 years) primaries. Symptoms were in general
non-speciﬁc and reﬂected the anatomic site of involvement,
affecting the following areas in order of frequency: scalp
skin (40.4%), ear and temporal bone (26%), and sinonasal
tract (24%). The tumors ranged in size from 0.5 up to 8 cm,
with a mean size of 2.3 cm. Histologically, the majority of
tumors were meningothelial (77.4%), followed by atypical
(7.5%), psammomatous (4.1%) and anaplastic (2.7%).
Psammoma bodies were present in 45 tumors (30.8%), and
bone invasion in 31 (21.2%) of tumors. The vast majority
were WHO Grade I tumors (87.7%), followed by Grade II
(9.6%) and Grade III (2.7%) tumors. Immunohistochemi-
cally, the tumor cells labeled for EMA (76%; 61/80), S-100
protein (19%; 15/78), CK 7 (22%; 12/55), and while
there was ki-67 labeling in 27% (21/78), \3% of cells
were positive. The differential diagnosis included a number
of mesenchymal and epithelial tumors (paraganglioma,
schwannoma, carcinoma, melanoma, neuroendocrine ade-
noma of the middle ear), depending on the anatomic site of
involvement. Treatment and follow-up was available in 110
patients: Biopsy, local excision, or wide excision was
employed. Follow-up time ranged from 1 month to
32 years, with an average of 14.5 years. Recurrences were
noted in 26 (23.6%) patients, who were further managed by
additional surgery. At last follow-up, recurrent disease was
persistent in 15 patients (mean, 7.7 years): 13 patients were
dead (died with disease) and two were alive; the remaining
patients were disease free (alive 60, mean 19.0 years, dead
35, mean 9.6 years). There is no statistically signiﬁcant
difference in 5-year survival rates by site: ear and temporal
bone: 83.3%; nasal cavity: 81.8%; scalp skin: 78.5%; other
sites: 65.5% (P = 0.155). Meningiomas can present in a
wide variety of sites, especially within the head and neck
region. They behave as slow-growing neoplasms with a
good prognosis, with longest survival associated with
younger age, and complete resection. Awareness of this
diagnosis in an unexpected location will help to avoid
potential difﬁculties associated with the diagnosis and
management of these tumors.
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Introduction
Meningioma is a well-recognized tumor of the central
nervous system (CNS) that typically arises in proximity to
the meninges. These neoplasms are more common in
females during the middle decades of life and account for
24–30% of primary intracranial tumors [1]. Most com-
monly extra-neuraxial, meningiomas are found overlying
the surface of the brain or at the skull base [2]. Uncom-
monly, meningiomas occur in intraventricular [3, 4], in-
traparenchymal [2, 5], or intraosseous locations. In rare
instances (\2%), they appear as an extracranial tumor,
most often in the head and neck region [2–20], and spe-
ciﬁcally in the sinonasal tract [20], ear and temporal bone
[19], and scalp [21]. The histopathologic diagnosis is
usually straightforward; however, the diagnosis may pose
challenges in these unexpected locations where the differ-
ential diagnosis includes paraganglioma, carcinoma, mel-
anoma, schwannoma, and olfactory neuroblastoma, among
others. Previous reports on meningioma in uncommon
locations are largely limited to individual cases or small
series [2, 4–10, 12–16]. The objective of this retrospective
study is to present our experience, the largest series to date,
with extracranial meningiomas, highlighting clinicopatho-
logic features and outcome associated with the surgical
treatment of these tumors.
Materials and Methods
Study Population
The records of 205 patients with primary extracranial
meningiomas were retrieved from the registries of the
Otorhinolaryngic-Head and Neck Tumor Registry, Soft
Tissue Registry and the Neuropathology Registry of the
Armed Forces Institute of Pathology (AFIP) between the
years 1970 and 1999. The anatomic sites included ear,
temporal bone, sinonasal tract (including paranasal sinu-
ses), scalp, chest and thorax, pelvis and extremities. How-
ever, 59 patients were excluded from further consideration
because of at least one of the following reasons: (1) parafﬁn
blocks were unavailable for additional sections; (2) the
original submitted case did not have sufﬁcient demographic
information supplied to warrant inclusion or from which to
obtain adequate follow-up information; (3) patients with
primary tumors of the intracranial cavity, who later devel-
oped extra-cranial manifestations were excluded; (4) the
cases were diagnosed indeﬁnitely, using terms such as
‘‘consistent with,’’ ‘‘suggestive of,’’ or ‘‘suspicious for.’’
The remaining 146 patients with meningioma compose the
subject of this study based upon adequate clinical infor-
mation, demographic ﬁndings, and materials for follow-up
and hematoxylin and eosin-stained slides to make a deﬁn-
itive diagnosis.
Materials within the ﬁles of the AFIP were supple-
mented by a review of the patient demographics, medical
history, surgical pathology and operative reports, oncology
data services, cancer registry records, and by written
questionnaires or oral communication with the treating
physician(s). Follow-up data tabulated included informa-
tion regarding the location of the primary site, the speciﬁc
treatment modalities used, and the current status of the
disease and patient. Extent of resection was deﬁned as
partial (P) or gross total resection (GTR) based on infor-
mation coded at the treating institution. This clinical
investigation was conducted in accordance and compliance
with all statutes, directives, and guidelines of the Code of
Federal Regulations, Title 45, Part 46, and the Department
of Defense Directive 3216.2 relating to human subjects in
research.
Pathological Investigation
The macroscopic pathology observations noted within this
study were gathered from the individual gross descriptions
of the neoplasms given by the contributing pathologists.
In all cases, tumor tissue consisted of formalin ﬁxed,
routinely processed, and parafﬁn embedded surgical
specimens. Hematoxylin and eosin-stained slides from all
cases were reviewed to conﬁrm the diagnosis of menin-
gioma by all four neuropathologists (EJR, JPB, GDS, and
HM) and an otorhinolaryngic pathologist (LDRT), inde-
pendently initially, and followed by a consensus confer-
ence for any case that raised a diagnostic differential
consideration or was a Grade II or Grade III tumor.
Meningiomas were assessed and classiﬁed according the
World Health Organization 2000 and 2007 [1, 22].
Mitoses were counted by examining 10 high power ﬁelds
(HPF) for each tumor in the region of highest cellularity
and determining an average number per 10 HPF. Lesions
were considered atypical if they possessed a mitotic rate
greater than four per 10 high-power ﬁelds (2.5 mm
2)
[23, 24] and/or had at least three of the following histo-
logic features: hypercellularity, growth of tumor cells in
sheets, prominent nucleoli, necrosis, and small cell for-
mation [1, 22].
Immunophenotypic analysis was performed in 80 cases
using the standardized avidin-biotin method, using 4 lm
thick, formalin- ﬁxed, parafﬁn-embedded sections. Table 1
documents the pertinent, commercially available
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was performed on a single representative block in each
case. When required, proteolytic antigen retrieval was
performed with predigestion for 3 min with 0.05% Prote-
ase VIII (Sigma Chemical Co, St. Louis, MO, USA) in a
0.1 M phosphate buffer at a pH of 7.8 at 37C. Antigen
enhancement (recovery) was performed, as required, using
formalin-ﬁxed, parafﬁn-embedded tissue treated with a
buffered citric acid solution and heated for 20 min in a
calibrated microwave oven. Following this, the sections
were allowed to cool at room temperature in a citric acid
buffer solution for 45 min before continuing the procedure.
Standard positive and negative (serum) controls were used
throughout. The antibody reactions were graded as weak
(1?), moderate (2?), and strong (3?) staining, and the
fraction of positive cells was determined by separating the
percentage of positive cells into four groups: \10%, 10–
50%, 51–90%, and [90%. To quantify the percentage of
nuclei staining with Ki-67, at least 500 tumor cells were
manually counted; three separate counts were performed in
the region of tumor with highest nuclear staining, and an
average percentage of positively stained nuclei was
calculated.
A review of publications in English (MEDLINE 1966–
2008) was performed, and all cases primarily involving the
ear and temporal bone, skin, orbit, oral cavity, nasal cavity,
nasopharynx, paranasal sinuses, soft tissues, and solid
organs (lung, liver, spleen) and hollow organs (colon,
bladder, uterus, stomach) were included in the review.
Cases of cranial cavity or spinal canal meningiomas which
metastasized to distant sites were not included in the
review, unless they involved the sites described above.
Non-English articles were not included.
Statistics
Survival probabilities were calculated according to the
Kaplan–Meier method and were measured from the date of
diagnosis until the date of last follow-up or until death.
Bivariate associations between survival and prognostic
factors were tested using the log-rank test. Multivariate
associations between survival and prognostic factors were
tested using the Cox proportional hazards regression. Cat-
egorical variables were analyzed using Chi-square tests to
compare observed and expected frequency distributions.
Comparison of means between groups were made with
unpaired t tests. Conﬁdence intervals of 95% were gener-
ated for all positive ﬁndings. The alpha level was set at
P\0.05. Statistical analysis was performed using SPSS
version 12.0 for Windows (SPSS, San Diego, CA) and
STATA version 8.1 for Windows (Stata Corporation,
College Station, TX). Often the date of last follow-up was
given as month and year, but no day was available. In those
cases, follow-up was calculated to the 15th day of the
month.
Results
Clinical
The patients included 74 females and 72 males (Table 2).
There was a statistically signiﬁcant gender difference based
on anatomic site (P = 0.044), with a greater number of
men among patients with scalp skin lesions (63%) and a
greater number of women among ear lesions (66%).
Patients’ age at presentation ranged from 3 months to
Table 1 Immunohistochemistry panel
Antigen/antibody Primary antibody Company Dilution Antigen recovery
Vimentin rp Dako, Carpinteria, CA 1:200 n/a
Epithelial membrane antigen (EMA) mm Dako 1:100 Protease digestion
Cytokeratin (AE1/AE3 and CK1) mm Boehringer Mannheim Biochemicals,
Indianapolis, IN, and Dako
1:50
1:200
Protease treatment
CK7 mm Dako 1:200 Protease digestion
S-100 protein rp Dako 1:800 n/a
CAM5.2 mm Ventana, Tucson, AZ 1:100 Protease digestion
Synaptophysin rp Dako Neat Protease digestion
CK20 mm Dako 1:50 Protease digestion
Glial ﬁbrillary acidic protein (GFAP) rp Dako 1:2000 Protease digestion
Chromogranin mm Dako 1:100 n/a
Synuclein mm Novacastra, New Castle, UK 1:80 Microwave
Ki67 mm Immunotech, Westbrook, ME 1:20 Microwave
mm mouse monoclonal, rp rabbit polyclonal
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42.4 years. The average age at presentation for women was
older than men, at 45.6 and 39.6 years, respectively, but
this difference did not reach statistical signiﬁcance
(P = 0.09); likewise, there was no statistical difference
between genders when stratiﬁed for speciﬁc site (even
though the average age for patients with nasal cavity
tumors in males versus females was 42.1 versus
51.4 years). Ear and temporal bone tumors had an older
mean age at presentation when compared to scalp skin and
other soft tissue lesions: 50.1 versus 36.2 years
(P = 0.004) and 35.6 years (P = 0.042), respectively. A
possible explanation may be entrapped meningeal tissue
during embryologic development, which undergoes neo-
plastic transformation and comes to clinical attention
before an intraosseous lesion.
Patients symptoms were referable to the anatomic site of
tumor involvement. Skin scalp lesions and neck lesions
presented with a mass. Tumors from the ear and temporal
bone presented with hearing changes, either sensorineural
or conductive hearing loss, otitis, headaches, dizziness,
unsteadiness, vertigo, disequilibrium, tinnitus, otalgia, and
bleeding. Facial nerve or other cranial nerves were
involved in 4 patients. Patients with tumors arising in the
nasal cavity presented with a mass lesion, epistaxis,
sinusitis, pain, and/or obstructive symptoms. Four patients
in this group also had visual changes, including blindness,
possibly related to pressure effect from the mass as it
expanded in size, although the blindness did not resolve
after the tumors were removed. None of the patients in this
series were asymptomatic, although sometimes the ‘‘skin
nodule’’ or ‘‘tumor’’ was not clinically worrisome to the
patient and may have been an incidental ﬁnding during
examination for a different reason. Although not available
in all patients, when questioned, no patients reported being
part of a kindred with von Recklinghausen’s disease or any
other phakomatosis.
The duration of symptoms ranged from 2 weeks to
240 months, with an average of 27.1 months. The overall
long duration of symptoms is most likely related to the
generally nonspeciﬁc nature of the initial symptoms, and
patients were frequently managed without a speciﬁc diag-
nosis. There was no difference in average symptom dura-
tion between the genders (female 27.0 months, male
27.3 months). When contiguous adjacent anatomic sites
were involved, the symptom duration was generally shorter
than patients whose tumor involved a single site: ear and
temporal bone sites: 7.6 months; nasal cavity and paranasal
sinuses: 31.3 months versus external auditory canal:
47.3 months and nasal cavity alone: 36.5 months.
Radiographic procedures were performed in the major-
ity of patients with ear and temporal bone and nasal cavity
lesions, but generally not performed in the evaluation of
skin and soft tissue cases. In general, by computed
tomography scans, a mass was identiﬁed, sometimes
interpreted to represent an infectious or inﬂammatory
condition. Generally, bony destruction was not identiﬁed,
although displacement, sclerosis or remodeling was seen,
especially in the sinonasal cavity cases. Speciﬁcally, a
central nervous system (CNS) connection was generally
not identiﬁed in the majority of patients where tests had
been performed (81.4%), especially in the patients who had
radiographic studies interpreted as normal (40%).
Table 2 Clinical characteristic of 146 extracranial meningiomas
Clinical characteristics N = 146
Gender
Females 74
Ear and temporal bone 25
Nasal cavity and nasopharynx 19
Other (soft tissue, neck) 8
Skin—scalp 22
Males 72
Ear and temporal bone 13
Nasal cavity and nasopharynx 16
Other (soft tissue, neck) 6
Skin—scalp 37
Age (in years)
Range 0.25–88
Ear and temporal bone 10–80
Nasal cavity and nasopharynx 4–88
Other (soft tissue, neck) 9–71
Skin—scalp 0.3–84
Mean 42.4
Females 45.6
Males 39.6
Ear and Temporal bone 50.1
Females 51.6
Males 47.2
Nasal cavity and nasopharynx 47.1
Females 51.4
Males 42.1
Other (soft tissue, neck) 35.6
Females 31.0
Males 42.0
Skin—scalp 36.2
Females 39.0
Males 34.5
Symptom duration (in months)
Range 0.5–240
Mean 27.1
Females (mean) 27.0
Males (mean) 27.3
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extension of the tumor into the base of the skull was noted.
Still, the tumor bulk was extraneuraxial. Magnetic reso-
nance with a T1-weighted, gadolinium diethylene triamine
pentoacetic acid (Gd-DTPA) enhancement helped under-
score the nature of the lesion and the extent of the tumor.
Pathologic Features
Macroscopic
The vast majority of tumors affected the skin of the scalp
(Table 3). There was no particular predilection anatomi-
cally, with forehead, vertex, occipital, frontal, parietal and
temporal locations stated. It would be difﬁcult to extrapo-
late association with the cranial bone suture lines, but some
of the tumors were probably overlying these landmarks.
The ear and temporal bone tumors occurred in the
middle ear alone (n = 26), external auditory canal only
(n = 4), temporal bone only (n = 2), and involving the
temporal bone, middle ear, external auditory canal and
eustachian tube combined (n = 6). Tumors were unilateral.
The tumors ranged in size from 0.5 to 4.5 cm, with a mean
size of 1.2 cm. There was a statistically signiﬁcantly larger
size for tumors which arose in the temporal bone (mean
2.8 cm), as opposed to the external auditory canal (mean
1.1 cm), middle ear (mean 1.1 cm), or mixed (1.2 cm)
(P = 0.02).
The sinonasal tract tumors occurred in the nasal cavity
alone (n = 17), nasopharynx alone (n = 5), frontal or
ethmoid sinus alone (n = 3), sphenoid sinus alone (n = 2),
and in the nasal cavity and the paranasal sinuses (n=8),
including ethmoid, frontal, sphenoid, and/or maxillary
sinus (Table 3). Five patients presented with bilateral nasal
cavity disease. The tumors ranged in size from 1.0 to
8.0 cm, with a mean size of 3.5 cm.
The other anatomic sites included the neck (n = 4),
pelvic bones or intra-abdominal cavity (n = 3), soft tissues
of the back and Achilles tendon (n = 3), orbit (n = 2),
mandible (n = 1) and parotid gland (n = 1). Speciﬁc
information about the size of the lesion was not available in
these soft tissue locations.
The cut surface, when not submitted in multiple frag-
ments, was composed of grayish white-tan to pink, gritty,
ﬁrm to rubbery masses. The ear, temporal bone, and sin-
onasal tract tumors were often insinuated into bone,
although the surface epithelium was intact (either squa-
mous or respiratory, respectively). Calciﬁcations were
identiﬁed in the fragments of tissue, but may have included
the bone rather than representing psammoma bodies.
Microscopic
The tumors were separated into a variety of histologic
types and grades. Overall, there were 113 meningothelial
(Fig. 1), 11 atypical, 6 psammomatous, 4 transitional, 4
anaplastic, 3 metaplastic, 2 clear cell, 2 ﬁbrous, and 1
angiomatous meningioma(s). Overall, there were 128
WHO Grade I, 14 WHO Grade II, and 4 WHO Grade III
tumors. By deﬁnition, atypical and clear cell types are
WHO Grade II tumors, while anaplastic meningioma is
Table 3 Macroscopic ﬁndings of 146 extracranial meningiomas
Extracranial meningiomas
Anatomic site
Skin—scalp 59
Middle ear 26
Nasal cavity alone 17
Nasal cavity and paranasal sinuses 8
Ear and temporal bone (mixed) 5
Nasopharynx alone 5
External auditory canal 4
Neck 4
Intra-abdominal/pelvis 3
Sinus alone (frontal, ethmoid, sphenoid) 5
Soft tissues 3
Orbit 2
Temporal bone 2
Mandible 1
Parotid gland 1
Extension into eustachian tube 1
Size (in cm)
Range 0.5–8.0
Mean 2.3
Fig. 1 Meningothelial meningioma from the left middle turbinate of
a 40 year old male who presented with rhinorrhea and recurrent
epitaxis
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based on anatomic site and as an overall percentage of each
tumor type in each anatomic site (Table 4). In general, ear
and temporal bone, scalp skin, and sinonasal tract tumors
were meningothelial (77.4%), with almost all (95%) ear
and temporal bone tumors within this category. Speciﬁc
tumor types were as follows:
Atypical (7.5%, n = 5 nasal cavity, n = 4 soft tissues,
n = 2 scalp);
Psammomatous (4.1%, n = 2 ear, n = 2 scalp, n=1
back skin, n = 1 neck);
Transitional (2.7%, n = 2 nasal, n=2 scalp);
Anaplastic (2.7%, n=3 scalp, n=1 retroperitoneum);
Metaplastic (2.1%, n=2 nasal, n=1 scalp);
Clear cell (1.4%, n=1 pelvis, n=1 scalp);
Fibrous (1.4%, n=2 scalp); and
Angiomatous (0.7%, n=1 nasal) types.
In general, the tumors were composed of lobules and
whorls of neoplastic epithelioid cells with indistinct bor-
ders. The nuclei were generally round to oval nuclei with
delicate nuclear chromatin and occasional intranuclear
pseudo-inclusions. Intranuclear inclusions were present in
71% of cases, although they were not always abundant or
easy to ﬁnd. Psammoma bodies were frequently identiﬁed
(n=45), although less frequently in the soft tissue and
scalp tumors than in other tumor locations. The tumors
often had an ‘‘inﬁltrative’’ appearance, extending into the
adjacent tissues. These tissues may be soft tissue, skeletal
muscle, or bone (n = 31). The bone was often remodeled,
with islands of tumor inﬁltrating between the bony tra-
becular. However, the presence of ‘‘invasion’’ did not seem
to correlate with patient outcome. For the non-skin
primaries, the surface epithelium was intact, lacking
ulceration or erosion, suggesting a slow growth rate. The
other histologic types showed features unique to each
entity:
(a) Fibrous spindle cell pattern with cells resembling
ﬁbroblasts in interlacing patterns with collagen;
(b) Transitional less well developed fascicles of ﬁbro-
blast-like cells with more conspicuous whorling
(c) Angiomatous prominent vascular pattern within
meningioma
(d) Psammomatous abundant psammoma bodies, often
showing conﬂuent calciﬁcations;
(e) Metaplastic lipidized cells, xanthomatous or myxoid
changes.
(f) Clear cell patternless proliferation of polygonal cells
with cleared cytoplasm.
Atypical meningiomas have increased mitotic activity
along with increased cellularity, small cells with high
nuclear to cytoplasmic ratio, patternless or sheet-like
Table 4 Microscopic features of 146 extracranial meningiomas
Microscopic characteristic Extracranial
meningiomas
Subtype
Meningothelial 113 (77.4%)
Ear and temporal bone (36/38) 94.7%
Nasal cavity and nasopharynx (25/35) 71.4%
Other (soft tissue, neck) (6/14) 42.9%
Skin—scalp (46/59) 78.0%
Atypical 11 (7.5%)
Ear and temporal bone (0/38) 0
Nasal cavity and nasopharynx (5/35) 14.3%
Other (soft tissue, neck) (4/14) 28.6%
Skin—scalp (2/59) 3.4%
Psammomatous 6 (4.1%)
Ear and temporal bone (2/38) 5.3%
Nasal cavity and nasopharynx (0/35) 0
Other (soft tissue, neck) (2/14) 14.3%
Skin—scalp (2/59) 3.4%
Anaplastic 4 (2.7%)
Ear and temporal bone (0/38) 0
Nasal cavity and nasopharynx (0/35) 0
Other (soft tissue, retroperitoneum) (1/14) 7.1%
Skin—scalp (3/59) 5.1%
Transitional, clear cell, ﬁbrous, metaplastic,
angiomatous
12 (8.3%)
Ear and temporal bone (0/38) 0
Nasal cavity and nasopharynx (5/35) 14.3%
Other (soft tissue, neck) (1/14) 7.1%
Skin—scalp (6/59) 10.2%
Grade
I 128 (87.7%)
Ear and temporal bone (38/38) 100.0%
Nasal cavity and nasopharynx (30/35) 85.7%
Other (soft tissue, neck) (8/14) 57.1%
Skin—scalp (52/59) 88.1%
II (includes atypical and clear cell type) 14 (9.6%)
Ear and temporal bone (0/38) 0
Nasal cavity and nasopharynx (5/35) 14.3%
Other (soft tissue, neck) (5/14) 35.7%
Skin—scalp (4/59) 6.8%
III (anaplastic) 4 (2.7%)
Ear and temporal bone (0/38) 0
Nasal cavity and nasopharynx (0/35) 0
Other (soft tissue, neck) (1/14) 7.1%
Skin—scalp (3/59) 5.1%
Bone invasion present 31
Psammoma bodies 45
Pseudoinclusions 104
Mitotic ﬁgures[2/10 HPF 15
HPF high power ﬁeld
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nent nucleoli were also identiﬁed in these tumors. By
deﬁnition, clear cell and chordoid meningiomas are Grade
II.
Finally, four tumors showed profound pleomorphism,
remarkably increased mitotic activity (mean, 24/10 HPF),
and signiﬁcant necrosis. These tumors developed in the
retroperitoneum (n=1), and scalp skin (n=3). Two
patients were lost to follow-up, one had died with local
disease (3.4 years), and one patient was alive without
evidence of disease (10.2 years).
A particularly remarkable ﬁnding was cholesteatoma in
association with the meningioma in 9 ear and temporal
bone cases. This ﬁnding was not associated with a high
recurrence rate: when a cholesteatoma was present, 22.2%
of patients developed a recurrence versus 29.6% of patients
without a cholesteatoma developed recurrent tumor.
Immunohistochemistry
Immunohistochemical stains showed strong and diffuse
vimentin immunoreactivity in all tumor cells in all cases
tested (n=78) (Table 5). Epithelial membrane antigen
(EMA) was identiﬁed in 61 of 80 cases tested, but the
immunoreactivity was focal and generally weak (Fig. 2),
accenting only a few cells here and there, rather than
yielding a strong and diffuse immunoreactivity. Other
epithelial markers were also positive, including keratin
(AE1/AE3, CK1 cocktail) in 24%, CK7 in 21.8%, CAM5.2
in 5.6%, and CK20 in 1.9%. The immunoreactivity was in
selected cells and was a focal ﬁnding. Particularly notice-
able, was a ‘‘pre-psammoma’’ like immunoreactivity with
CK7. This stain highlighted the periphery of concretions in
a tight, concentric whorl, suggesting a pre-psammoma
body like deposition. S-100 protein stained the cytoplasm
and nucleus of a few tumor cells in 19.2% of cases. Syn-
aptophysin (4%) and GFAP (1.4%) were uncommon ﬁnd-
ings. Chromogranin was not reactive. Isolated tumor cells
showed nuclear labelling with Ki-67, although only 14
cases showed increased labelling of[4% (of the 78 cases
tested). These cases included all of the anaplastic menin-
giomas, 2 of the atypical meningiomas, and 8 men-
ingothelial meningiomas. Four of the meningothelial
meningiomas did not show mitotic ﬁgures on hematoxylin
and eosin stained material, but the biopsy size was limited
and so the proliferation index is probably more reliable.
Synuclein was tested in isolated cases (n=18), and was
negative in all cases tested.
Treatment and Follow-up
All patients were treated by partial or complete surgical
excision; complete surgical removal of the tumor was
frequently impossible to determine for the tumors of the
sinonasal tract and ear and temporal bone, while scalp skin
and soft tissue lesions were frequently completely
removed. Comments about the partial or complete excision
were supplied by the operating surgeons, since the frag-
mentation of the specimen precluded a histologic deter-
mination. A few patients were subsequently treated with
chemotherapy (n=1), and radiation therapy (n=5), one
for recurrent disease. Patient follow-up was available for
110 patients (of the 146 in the study). The following
information is set in that context, with percentages based
only on the 110 patients in whom follow-up was available.
Overall, the patients were followed for an average of
14.5 years, with a range of 0.1 up to 32.1 years (Table 6).
The majority of patients (n=97) were alive (n=62) or
had died (n=35) of unrelated causes, yielding a raw
Table 5 Immunohistochemical proﬁle of extracranial meningiomas
Antibody Number of cases
with positive reactions
Vimentin 78/78 (100%)
Epithelial membrane antigen (EMA) 61/80 (76.3%)
Cytokeratin (AE1/AE3 and CK1) 18/75 (24.0%)
CK7 12/55 (21.8%)
S-100 protein 15/78 (19.2%)
CAM5.2 3/54 (5.6%)
Synaptophysin 3/75 (4.0%)
CK20 1/52 (1.9%)
GFAP 1/69 (1.4%)
Chromogranin 0/72 (0%)
Synuclein 0/18 (0%)
Ki-67 index ([1%) 21/78 (26.9%)
Fig. 2 Immunostaining with epithelial membrane antigen labels the
meningothelial cells
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evidence of disease at last follow-up: 2 were alive (mean
14.5 years), and 13 had died with disease (mean 6.6 years).
It is important to state that these patients died with disease,
but not ‘‘from’’ their disease. After accounting for
differential lengths of follow-up using the Kaplan-Meier
method, median overall survival in this cohort was
28.4 years. Five-year and 10-year survival rates are 79.9%
and 73.1%, respectively. Median disease-speciﬁc survival
could not be estimated because of the low number of deaths
Table 6 Follow-up, survival and prognostic markers for 110 patients with extracranial meningioma
Deaths from all causes Deaths from disease
Number of
patients
Follow-up
(person-years)
Deaths 5-year
survival
10-year
survival
P value* Deaths 5-year
survival
10-year
survival
P value*
All patients 110 1,596 48 0.799 0.731 13 0.912 0.901
Recurrence 0.174 0.00
No 84 1,263 34 0.845 0.770 2 0.988 0.988
Yes 26 333 14 0.642 0.599 11 0.674 0.629
Anatomic site 0.155 0.763
Ear/temporal bone 36 551 10 0.833 0.772 5 0.884 0.851
Sinonasal tract 33 511 16 0.818 0.755 5 0.938 0.938
Scalp skin 33 429 17 0.785 0.691 2 0.931 0.931
Other 8 104 5 0.625 0.625 1 0.857 0.857
Histologic subtype 0.076 0.378
Meningothelial 87 1,286 37 0.815 0.728 10 0.915 0.901
Psammomatous 5 103 – 1.000 1.000 – 1.000 1.000
Clear cell 1 11 – 1.000 1.000 – 1.000 1.000
Atypical 10 121 6 0.700 0.700 1 0.875 0.875
Anaplastic 2 14 2 0.500 0.500 1 0.500 0.500
Misc 5 62 3 0.600 0.600 1 1.000 1.000
Grade 0.052 0.133
I 97 1,450 40 0.813 0.736 11 0.924 0.911
II 11 132 6 0.727 0.727 1 0.889 0.889
III 2 14 2 0.500 0.500 1 0.500 0.500
Extent of procedure 0.857 0.828
Complete 100 1,447 44 0.799 0.724 12 0.913 0.901
Partial 10 149 4 0.800 0.800 1 0.900 0.900
Gender 0.974 0.017
Female 58 834 25 0.790 0.736 11 0.856 0.856
Male 52 762 23 0.808 0.724 2 0.981 0.956
Age at diagnosis 0.005 0.049
\40 years 41 700 11 0.876 0.850 2 0.972 0.944
[40 years 69 895 37 0.754 0.661 11 0.877 0.877
Necrosis 0.010 0.009
Absent 105 1,560 44 0.818 0.747 11 0.929 0.918
Present 5 36 4 0.400 0.400 2 0.500 0.500
Proliferation Index 0.047 0.101
\4% 43 533 20 0.670 0.622 5 0.891 0.859
C4% 11 114 7 0.727 0.546 3 0.727 0.727
Unknown 56 949 21 0.911 0.853 5 0.963 0.963
Cholesteatoma 0.125 0.925
Yes 9 126 1 0.889 0.889 1 0.889 0.889
No 101 1,470 47 0.791 0.718 12 0.915 0.903
* P value from log rank test
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speciﬁc time points are: 91.2% at 5 years, 90.1% at
10 years, 90.1% at 15 years, 86.2% at 20 years, 86.2% at
25 years, and 75.4% at 30 years. These ﬁndings show that
while a few patients die of their disease soon after dis-
covery, the majority of patients survive a long time with
death resulting from other causes rather than from tumor.
However, the continued progression of the disease for
decades indicates that long term clinical follow-up is
required to monitor disease progression or recurrence.
Twenty-six patients developed a recurrence. Recur-
rences found within a few months of the initial surgery
probably represent residual disease after incomplete exci-
sion of the primary rather than representing true recurrence.
Recurrences develop in the same site and on the same side
as the previous tumor, often yielding a slightly more
‘‘inﬁltrative’’ pattern than the initial specimen. Tumors
which extend into the base of the skull (ear/temporal bone
and sinonasal tract tumors) tend to be very difﬁcult to
eradicate surgically, and tend to remain indolent for many
years. While overall patients with recurrences experienced
a good survival (median, 15.6 years), 42.3% of these
patients died of their disease, 32.6% within 5 years of
initial diagnosis. This contrasts with only 1.2% of patients
without recurrences dying of disease within 5 years of
diagnosis (P\0.001). Overall survival was lower among
patients with recurrences but this difference was not sta-
tistically signiﬁcant (median 31.4 years among patients
without recurrence versus 15.6 years among patients with
recurrences, P = 0.174). Recurrence appears to increase
the risk of dying from disease.
The speciﬁc anatomic site of tumor development sug-
gests that 5-year disease-speciﬁc survival is slightly higher
among patients with scalp skin based tumors (93.1%) and
tumors of the sinonasal tract (93.8%) in comparison to
tumors of other soft tissue sites (85.7%) and ear and tem-
poral bone (88.4%). However, as there are only a few cases
within each group, a statistically signiﬁcant result could not
be measured (P = 0.763).
The histologic type does seem to correlate with dying
from disease (P = 0.0378), although this ﬁnding could not
be controlled for recurrence speciﬁcally. There were no
deaths from disease among the 6 patients with psammo-
matous or clear cell type tumors; ten among the 87 patients
with meningothelial meningiomas (5-year survival 91.5%);
and 1 among the ten patients with atypical tumors (5-year
survival 87.5%). Although ﬁve-year survival was only 50%
among patients with anaplastic tumors, this represents one
death from disease among two patients.
Aswouldbeexpected,agreaterpercentageofpatientsdie
from their disease as the grade of the tumor increases. Five-
year disease speciﬁc survival decreases from 92.4% (Grade
I)to88.9%(GradeII)toonly50%(GradeIII).Further,itcan
beseenthattheoveralldurationofsurvivalalsodecreasesas
the grade of tumor increases. However, because only 13
patients had Grade II or III tumors, these differences did not
reach statistical signiﬁcance (P = 0.052 for overall sur-
vival; P = 0.133 for disease-speciﬁc survival).
Data about the completeness of the excision is difﬁcult
to comment on, as this is not a parameter which can be
easily assessed nor conﬁrmed. Therefore, while it may
seem that the survival is shorter for patients with a partial
removal, with only a single death from disease in this
group, it makes a meaningful interpretation difﬁcult.
Based on the data in this study, the overall 5-year sur-
vival for males and females is not different: females,
79.0%; males, 80.8%, P = 0.974. However, 14.4% of
women died from their disease within 5 years of diagnosis,
while only 1.9% of men died of their disease. This infor-
mation suggests that female patients have an overall worse
prognosis in comparison to male patients (P = 0.017).
It is difﬁcult to deﬁne outcome based on age, but using a
40 year age cut-off, there is a statistically signiﬁcant dif-
ference in patient outcome and length of survival. Two of
41 patients diagnosed before age 40 died of disease (5-year
survival 97.2%), compared with 11 of 69 patients diag-
nosed after age 40 (5-year survival 87.7%, P = 0.049).
Overall survival was also greater among younger patients
(P = 0.005), indicating that age may be an important
prognostic factor. It goes without saying that patients with
necrosis (n=5), tend to survive for a shorter period. Four
of the 5 patients with necrosis died during the study (5-year
survival 40.0%), two from their disease (5-year disease-
speciﬁc survival 50%). These data indicate a poor prog-
nosis for patients with necrosis when compared with other
patients (overall 5-year survival 81.8%, P = 0.010; 5-year
disease-speciﬁc survival 92.9%, P = 0.009).
Overall survival is similar for patients with and without
an increased proliferation index during the ﬁrst 5 years
after diagnosis. Five year overall survival is 66.9% among
those with a proliferation index\4, compared with 72.7%
among those with a proliferation index C4. However,
patients with an increased proliferation index ([4) have
higher death rates overall, with median survival of only
10.2 years compared to 31.4 among those with prolifera-
tion index \4, and 10-year survival of 54.6% compared
with 62.2% among those with proliferation index \4
(P = 0.047). Disease-speciﬁc survival was also lower
among those with an increased proliferation index, but this
difference did not reach statistical signiﬁcance.
There are no signiﬁcant differences between patients
who have cholesteatoma and patients who do not have
cholesteatoma with respect to all-cause survival
(P = 0.125) or disease-speciﬁc survival (0.925).
A ﬁnal comment regarding patient management and
outcome: the anatomic sites of the head and neck,
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nasal sinuses, and even the scalp skin can result in dis-
ruption of the adjacent tissues. A number of patients
developed mastoiditis, sinusitis, or scalp abscesses. These
complications resulted in seeding to the peripheral blood to
cause systemic sepsis, which resulted in the patient’s death.
Therefore, in these patients, even though they may not have
residual tumor, the deaths are a direct result of the man-
agement for the tumor. Therefore, it is important to con-
sider the inherent risks of surgeries in these vital structures.
Clinicopathologic Correlations
In summary, older patients, patients with necrosis, and
patients with increased proliferation index had signiﬁcantly
reduced overall survival. Women, patients older than
40 years at diagnosis, and patients with recurrence or
necrosis were signiﬁcantly more likely to die of disease
(P\0.05 log rank test; Table 6). When all potential
prognostic factors were evaluated jointly using Cox pro-
portional hazards regression, the only independent predic-
tor of overall survival was age group; when non-signiﬁcant
variables were removed sequentially from the model, the
remaining signiﬁcant prognostic factors were age group,
anatomical site and presence of necrosis (Table 7). Mor-
tality was more than three times higher among patients
whose age was greater than 40 years than among those
younger than 40 years at diagnosis (hazard ratio 3.6, 95%
conﬁdence interval 1.8–8.0). We had hypothesized that
grade would be a stronger predictor of survival than either
Table 7 Estimated hazard ratios, Cox proportional hazards models
Prognostic factor Full model Reduced model**
Hazard ratio 95% CI* P Hazard ratio 95% CI* P
All-cause mortality
Recurrence 1.43 0.72–282 0.31
Site (vs. Ear) 0.20 0.02
Nasal 2.63 1.02–6.78 0.04 2.09 0.93–4.70 0.07
Skin scalp 1.78 0.66–4.81 0.25 3.12 1.36–7.19 0.01
Other 2.40 0.59–9.78 0.22 4.43 1.47–31.34 0.01
Grade II or III 0.81 0.22–3.00 0.76
Male 1.24 0.63–2.44 0.54
Age[40 3.79 1.80–8.00 0.00 3.53 1.74–7.15 0.00
Necrosis 3.44 0.70–16.81 0.13 2.84 0.97–8.34 0.06
Cholesteatoma 0.42 0.05–3.39 0.42
PI 0.12
PI[4% 0.78 0.24–2.51 0.68
Unknown PI 0.38 0.15–0.95 0.04
Disease-speciﬁc mortality
Recurrence 19.04 3.48–104.3 0.00 26.00 5.13–131.8 0.00
Site (vs. Ear) 0.21 0.08
Nasal 6.29 0.64–62.05 0.12 7.69 0.78–75.96 0.08
Skin scalp 0.32 0.03–3.46 0.35 0.38 0.07–2.08 0.26
Other 0.31 0.02–4.24 0.38 0.14 0.01–1.66 0.12
Male 0.46 0.08–2.80 0.40
Age[40 1.40 0.20–9.84 0.74
Necrosis 3.03 0.32–28.47 0.33
Cholesteatoma 1.06 0.11–10.02 0.96
PI 0.05 0.01
PI[4% 3.03 0.39–23.52 0.29 5.05 0.95–26.80 0.06
Unknown PI 0.09 0.01–0.94 0.04 0.08 0.01–0.85 0.04
* CI conﬁdence interval
** Variables in the reduced model were selected from among the variables in the full model using the backwards stepwise variable selection
algorithm implemented in SPSS version 14. Variables with P\0.10 were retained in the ﬁnal model
Head and Neck Pathol (2009) 3:116–130 125necrosis or proliferation index because both of these vari-
ables are part of the grading criteria. However, at least in
this population, necrosis is a better predictor of all-cause
mortality than either grade or proliferation index.
The best predictor of disease-speciﬁc survival was
recurrence. Adjusting for other prognostic factors, the
estimated hazard ratio associated with recurrence is 19
(95% conﬁdence interval 3.5–104.3). After adjusting for
recurrence, gender, age and necrosis were no longer sta-
tistically signiﬁcant, perhaps because women and patients
with necrosis were twice as likely as other patients to
experience recurrence. Patients with proliferation index of
4% or higher were three times more likely to die of disease
than patients with proliferation index below 4%, although
given the small number of patients this did not reach sta-
tistical signiﬁcance. Patients with unknown proliferation
index were 90% less likely to die of disease. When non-
signiﬁcant variables were removed from the regression
model sequentially, differences among sites reached sta-
tistical signiﬁcance. Compared with tumors of the ear, the
estimated risk of dying of disease was more than 7 times
higher for patients with nasal tumors, and more than 60%
lower for patients with skin scalp tumors.
Discussion
Arachnoid cells (arachnoid granulations, meningiocytes,
meningothelial cells, pacchionian bodies) are thought to
arise from neural crest. They normally line the inner aspect
of the arachnoid membrane, and ﬁll the cores of the
arachnoid villi that project into the lumens of dural veins
and venous sinuses. Increasing evidence supports the
development of meningiomas from arachnoid cap cells,
with different mechanisms to suggest how extracranial
meningiomas arise:
(1) Arachnoidal cells are present in the sheaths of nerves or
vessels where they emerge through the skull foramina.
(2) Displaced pacchionian bodies become detached,
pinched off, or entrapped during embryologic devel-
opment in an extracranial location.
(3) A traumatic event or cerebral hypertension that
displaces arachnoid islets.
(4) An origin from undifferentiated or multipotential
mesenchymal cells, such as ﬁbroblasts, Schwann
cells, or a combination of these, perhaps explaining
the diverse pathologic spectrum found in meningio-
mas. Consequently, by one mechanism or another,
arachnoid cells are identiﬁed outside the neuraxis and
give rise to meningiomas in extracranial locations,
including ear, sinonasal tract, scalp and soft tissues
[3, 8, 10, 14, 19–21, 25–39].
Up to 20% of intracranial meningiomas may have ex-
traneuraxial extension [10, 14, 19–21, 25–42], including
the skull, scalp (all cutaneous sites), orbit, upper airway
involvement (nasal cavity, paranasal sinuses, nasophar-
ynx), soft tissues, and ear and temporal bone. However,
when the scalp, orbit, sinonasal tract, oral cavity, and soft
tissues are excluded, the incidence decreases to less than
1% [19–21, 25, 27, 37, 38, 40, 43–45]. Based on our
ﬁndings, we believe the majority of our cases are arising de
novo from multipotential stem cell, although a number of
the cases within the ear and temporal bone and sinonasal
tract may develop from misplaced remnants of the pac-
chionian bodies. While there are a number of reported
cases of ‘‘ectopic’’ or ‘‘heterotopic’’ meningiomas, most of
these were reported prior to the modern improvement in
radiographic techniques which serves to more deﬁnitively
exclude intracranial disease. It is important to exclude an
intracranial component radiographically or during surgery
to yield the best possible management and follow-up. The
possibility of an intracranial tumor must always be con-
sidered if long term management is to achieve its intended
goal [8, 10, 19, 20, 34, 46].
Both genders were equally affected in this clinical series
in the aggregate (74 females and 72 males), although ear
and temporal bone tumors were more common in females
than males (2:1) and males were more commonly affected
than females for skin scalp lesions (1.7:1). This is in con-
trast to the reported predilection of intracranial tumors for
females [1].
Females tend to be signiﬁcantly older (mean 45.6 years)
than males (mean 39.6 years, P = 0.01), with the excep-
tion of soft tissue tumors where males tend to be older
(mean 42 years) than females (mean 31 years). Further,
patients with tumors of the skin scalp tend to present at a
younger mean age (36.2 years) than tumors which develop
in the ear and temporal bone (mean 50.1 years) and sino-
nasal tract (mean 47.1 years). This may be due to a greater
facility for clinical identiﬁcation of a skin scalp lesion
rather than an inner ear or sinonasal tract tumor. The
overall average age at presentation of our patients
(42.4 years) is not dissimilar from the middle-aged ﬁgure
used for intracranial meningiomas without any extracranial
extension. No patients in this clinical series had any syn-
drome-associated meningiomas.
Meningothelial meningiomas are the most common
tumor type identiﬁed in this clinical series. Interestingly,
95% of ear and temporal bone lesions were meningothelial,
but only 43% of soft tissue sites showed this pattern. This
suggests that a greater degree of vigilance is required to
render this diagnosis when looking at tumors in such
unusual anatomic sites as the parotid gland, Achilles ten-
don or the pelvis. Nearly one-third of meningiomas in the
soft tissues are atypical, further emphasizing the need for
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Atypical meningiomas [1, 22, 47] were diagnosed in 11
cases in this series. The soft tissue sites, including the neck
and pelvis, were most commonly affected, but the sino-
nasal tract and scalp skin were also affected by a few
tumors each. Interestingly, atypical histology did not por-
tend a worse outcome for these extracranial sites as it may
for intracranial lesions [19, 20, 24]. It may be they are
discovered at an early stage of development, allowing for
earlier surgery than their intracranial counterparts.
Axiomatic, the immunohistochemical proﬁle of extra-
cranial meningiomas is indistinguishable from intracranial
lesions; therefore, no ancillary technique can separate
direct extension from ectopic/extracranial meningioma.
Surprisingly, staining for CK7 was detected in 21.8% of
cases. Expression of CK7 in meningiomas has been pre-
viously reported [19, 20], speciﬁcally in secretory menin-
gioma [7]. In our series, expression was localized to
prepsammoma bodies, similar to those observed in secre-
tory meningiomas, but secretions were not seen in any of
the cases in this series. Therefore, it may be that the spe-
ciﬁc CK7 staining pattern may help with yielding a diag-
nosis of meningioma in these extracranial sites.
When receiving these cases in consultation, 24% of the
cases were incorrectly diagnosed, with a larger proportion
submitted as ‘‘undetermined.’’ This results in inadequate or
inappropriate management, especially if an intracranial
primary has not been excluded. The differential diagnosis
of extracranial meningiomas includes a variety of benign
and malignant neoplasms dependent upon the anatomic site
of involvement. Paraganglioma, schwannoma and meta-
static carcinomas are the most frequent misdiagnoses for
ear and temporal bone tumors [3, 19, 48]; carcinoma,
melanoma, olfactory neuroblastoma, and aggressive
psammomatoid ossifying ﬁbroma for sinonasal tract lesions
[6, 20, 49–51]; dermatoﬁbroma, melanoma, ﬁbrosarcoma,
leiomyosarcoma, and synovial sarcoma for soft tissue and
skin lesions, especially for Grade II or III tumors, and for
the non-meningothelial types of meningiomas.
The general histologic features and immunohistochem-
ical ﬁndings can usually separate between these tumors
[3, 6, 9]. Speciﬁcally, paraganglioma will show more of a
nested, Zellballen pattern, with granular cytoplasm and
chromogranin, synaptophysin, CD56, and S-100 protein
immunoreactivity (highlighting their respective compart-
ments). Schwannoma will demonstrate different degrees of
cellularity, with areas of myxoid change, perivascular
hyalinization, wavy nuclei, and strong, diffuse S-100 pro-
tein immunoreactivity. Metastatic carcinomas or carcinoma
in general tends to show more pleomorphism, a much
higher mitotic rate, and will be immunoreactive with a
variety of keratins. Whereas psammoma bodies can be seen
in papillary carcinomas (thyroid, lung, ovary), the growth
pattern of meningioma tends not to be papillary in these
extracranial sites. Melanoma (cutaneous or mucosal) can
mimic any tumor type, replete with intranuclear cytoplas-
mic inclusions and whorled architecture. However, pig-
ment, prominent, irregular nucleoli, and melanocytic
markers (including S-100 protein, HMB-45, melan-A,
MART1, tyrosinase, microphthalmia transcription factor)
will help to make the distinction. Olfactory neuroblastoma
occurs with direct proximity to the cribriform plate region,
usually maintains a lobular growth pattern of small to
intermediate cells with scant cytoplasm, has a ﬁbrillary
background, exhibits rosette and/or pseudorosette forma-
tions, and displays characteristic immunohistochemical
features (chromogranin, synaptophysin, neuron speciﬁc
enolase and CD56 tumor cell staining and S-100 protein
sustentacular staining) that are easy to separate from
meningiomas. An aggressive psammomatoid ossifying
ﬁbroma is an uncommon lesion which may be confused
with meningioma because both lesions occur in young to
middle-aged patients and may be associated with proptosis.
Both lesions have abundant psammoma bodies, but
meningiomas lack associated osteoclasts and osteoblasts.
Furthermore, the background stromal pattern is storiform
and more compact than a meningioma and does not have
the same immunophenotypic characteristics as a meningi-
oma. High grade tumors with pleomorphism, necrosis, and
increased mitotic activity with a loss of architecture, may
be very difﬁcult to separate from skin or soft tissue sar-
comas. Usually, small foci of recognizable meningioma
will be present, showing a vague whorling pattern. The
weak EMA may help, although EMA will be reactive in
synovial sarcoma. Speciﬁc sarcomas will generally exhibit
speciﬁc histologic, immunophenotypic or molecular results
that allow for their categorization apart from meningioma.
In general, the prognosis of extracranial meningiomas
appears to be excellent, with an overall median survival of
28 years. This is tempered by the speciﬁc anatomic site,
histologic type, tumor grade, gender, and age of the patient.
The recurrence rate for meningiomas after total excision
varies from 7% to 84% depending upon the number of
years of follow-up [13, 19, 22, 25, 47, 52, 53], with our rate
of 23.6% falling within this range. This is similar to
intracranial meningiomas which have a recurrence rate of
up to 20% and a mean survival around 7 years [1, 25, 52].
In this study, there was little difference between the 5
and 10-year disease-free survival rates (91.2% versus
90.1%, respectively), indicating that once the patients
survived disease free for 5 years, they were unlikely to die
with tumor. Furthermore, this same trend was noted at 15,
20, 25 and 30 years (90.1%, 86.2%, 86.2%, and 75.4%,
respectively). Nine of the thirteen patients who died of
their disease, died within the ﬁrst 5 years. The remaining
four patients died at 5.9, 15.6, 17.3, and 28.4 years,
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at 27.5 years. This ﬁnding supports the slow, indolent
growth of extracranial meningiomas, but also suggests very
long term clinical follow-up is necessary to achieve these
outcomes. Our ﬁndings are different from meningiomas in
general in which the recurrence rate increases with pro-
tracted follow-up (6% recurrence at 5 years and 20%
recurrence at 15 years [52]). Therefore, meticulous surgical
extirpation of extracranial meningiomas is important to
minimize the recurrence rate, without the necessity of
adjuvant therapy. While surgery is the treatment of choice,
there are a number of challenges due to the invasiveness of
the tumors and the complexity of the anatomy within the
sinonasal tract and ear and temporal bone, although scalp
and soft tissues lesions are no less difﬁcult to remove if
they are adjacent to vital structures. It may be necessary to
utilize a multidisciplinary approach with a combination of
intracranial, temporal bone, maxillofacial, and skull base
techniques to achieve total resection, possibly including
widely exenterative procedures to achieve this end [10, 16,
29, 31, 37, 54–61].
Five patients received radiation in this series. Radiation
therapy has been suggested to yield a possible improve-
ment in survival in meningiomas of the central nervous
system [13, 53, 57, 62]. However, this does not seem to be
the case in this series, although the numbers are limited:
One patient with recurrence, died of disease (0.5 years);
three patients are alive without evidence of disease (mean
14.2 years), and one patient died without evidence of dis-
ease (15.6 years). Further evaluation may be necessary in a
larger group of patients.
In our cases, and in those of the literature, when recur-
rences developed, they usually arise in the same anatomic
site as the primary lesion and depending on time interval,
may represent residual disease rather than recurrent tumor.
Metastatic disease did not occur in any of our patients nor
did we ﬁnd any convincing cases in the literature of
extracranial meningiomas resulting in metastasis.
Meningiomas that arise outside the skull are for the most
part benign tumors. Symptoms are associated with the
location of the lesion. Imaging studies may provide some
suspicion of diagnosis, but conﬁrmation relies on patho-
logic examination. The mainstay of treatment is complete
excision of the tumor by appropriate approaches, often
requiring multidisciplinary approach. The histologic fea-
tures, while generally ‘‘characteristic’’, especially for
meningothelial tumors, may be atypical, requiring separa-
tion from other tumor types, by both histologic and
immunohistochemistry studies. Separation from other
tumors is essential as extracranial meningioma seems to
have an excellent long term prognosis with only limited
recurrence.
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